M. Murray

Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study

R. Advani, Y. Oki, J. Radford, 2021, Annals of Hematology.

Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer.

W. Audeh, P. Whitworth, P. Beitsch, 2022, Surgical oncology.

Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature

K. Cowan, W. Audeh, P. Whitworth, 2022, JCO precision oncology.

Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy

W. Audeh, P. Whitworth, P. Beitsch, 2022, JCO precision oncology.

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

P. Whitworth, P. Beitsch, J. Pellicane, 2017, Annals of Surgical Oncology.

Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer

K. Cowan, W. Audeh, P. Whitworth, 2022, Annals of Surgical Oncology.